HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee

Newton A C S Wong, Fernanda Amary, Rachel Butler, Richard Byers, David Gonzalez, Harry R Haynes, Mohammad Ilyas, Manuel Salto-Tellez, Philippe Taniere

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.

Original languageEnglish
JournalJournal of Clinical Pathology
DOIs
Publication statusEarly online date - 08 Feb 2018

Fingerprint

Molecular Pathology
Adenocarcinoma
Guidelines
National Health Programs
Biological Products
Stomach
human ERBB2 protein
Pathologists
Pathology
Neoplasms
Proteins

Keywords

  • Journal Article
  • Review

Cite this

@article{c5cc5cfddd0449d4ae576c649fe20192,
title = "HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee",
abstract = "The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.",
keywords = "Journal Article, Review",
author = "Wong, {Newton A C S} and Fernanda Amary and Rachel Butler and Richard Byers and David Gonzalez and Haynes, {Harry R} and Mohammad Ilyas and Manuel Salto-Tellez and Philippe Taniere",
note = "{\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2018",
month = "2",
day = "8",
doi = "10.1136/jclinpath-2017-204943",
language = "English",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",

}

HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. / Wong, Newton A C S; Amary, Fernanda; Butler, Rachel; Byers, Richard; Gonzalez, David; Haynes, Harry R; Ilyas, Mohammad; Salto-Tellez, Manuel; Taniere, Philippe.

In: Journal of Clinical Pathology, 08.02.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee

AU - Wong, Newton A C S

AU - Amary, Fernanda

AU - Butler, Rachel

AU - Byers, Richard

AU - Gonzalez, David

AU - Haynes, Harry R

AU - Ilyas, Mohammad

AU - Salto-Tellez, Manuel

AU - Taniere, Philippe

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2018/2/8

Y1 - 2018/2/8

N2 - The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.

AB - The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.

KW - Journal Article

KW - Review

U2 - 10.1136/jclinpath-2017-204943

DO - 10.1136/jclinpath-2017-204943

M3 - Review article

C2 - 29439009

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

ER -